ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 25.04

+0.9%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (411)	4/7/2007 10:02:19 PM
From: tuck	of 588

No apologies needed; I was clearly confused, and your explanation is a big help. Goddam double negatives . . . If there's no distinction between inverse agonism and antagonism in terms of side effects, they a) think there is some value in shutting down the constitutive activity of the H1R, and/or b) think this is a way to end run the wall of IP around a major target, which would definitely be worth something if they outdo the potency of antagonists of said target with an inverse agonist. Again, I don't even have a clue that this is some action Acadia even has a piece of. These guys sometimes wander off into strange areas flying their flag for reasons us outsiders don't understand, like that BRET study of EGFR. Message 22815426 Anyhow, thanks for dropping by and helping out; hope all is well! Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next